ALKS - Alkermes plc
| Previous Close | 38.86 |
| Open | 39.40 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1400 |
| Day's Range | 37.01 - 40.52 |
| 52 Week Range | 37.01 - 71.22 |
| Volume | 1,506,525 |
| Avg. Volume | 627,215 |
| Market Cap | 6.242B |
| Beta (3Y Monthly) | 2.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.92 |
| Earnings Date | Oct 24, 2018 - Oct 29, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.17 |
- Thomson Reuters StreetEvents•4 hours ago
Edited Transcript of ALKS earnings conference call or presentation 23-Oct-18 12:30pm GMT
Q3 2018 Alkermes Plc Earnings Call
Motley Fool•12 hours agoAlkermes PLC (ALKS) Q3 2018 Earnings Conference Call Transcript
ALKS earnings call for the period ending September 30, 2018.
- Zacks•14 hours ago
Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook
Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.
- Zacks•17 hours ago
Alkermes (ALKS) Beats Q3 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of 216.67% and 5.22%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•18 hours ago
Alkermes: 3Q Earnings Snapshot
On a per-share basis, the Dublin-based company said it had a loss of 22 cents. Earnings, adjusted for one-time gains and costs, came to 7 cents per share. The results topped Wall Street expectations. The ...
- PR Newswire•19 hours ago
Alkermes Plc Reports Third Quarter 2018 Financial Results
-- Third Quarter Revenues Increased to $248.7 Million , Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.22 and Diluted Non-GAAP ...
- Benzinga•yesterday
Alkermes Q3 Earnings Preview
On Tuesday, Alkermes plc (NASDAQ: ALKS ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Wall Street expects ...
- Zacks•2 days ago
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
- Benzinga•2 days ago
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs
Biotech stocks are staging a rebound following the losses incurred in the week ended Oct. 12 amid catalysts that include the third-quarter earnings season and presentations at the European Society of Medical ...
- Zacks•5 days ago
Alkermes Boasts Strong Portfolio and Impressive Pipeline
Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.
- Zacks•6 days ago
EBS or ALKS: Which Is the Better Value Stock Right Now?
EBS vs. ALKS: Which Stock Is the Better Value Option?
Markit•6 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 26. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•7 days ago
Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress
DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando , Oct. 25-28, ...
- PR Newswire•7 days ago
Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial Results
DUBLIN , Oct. 16, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Tuesday, Oct. 23, 2018 , to discuss the company's ...
Markit•11 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 26. Index (PMI) data, output in the Healthcare sector is rising.
Markit•26 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 26. Index (PMI) data, output in the Healthcare sector is rising.
- GlobeNewswire•27 days ago
Consolidated Research: 2018 Summary Expectations for Pan American Silver, Invesco, Diodes, INVESCO MORTGAGE CAPITAL INC, Alkermes plc, and Golar LNG Partners LP — Fundamental Analysis, Key Performance Indications
NEW YORK, Sept. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- MarketWatch•28 days ago
Opioid legislation could lift certain hospital operators, drugmakers
New opioid legislation, which many expect will pass Congress by the end of the year, should benefit certain behavioral health providers and drugmakers, Height Capital Markets analyst Andrea Harris said on Wednesday. Among other provisions, the legislation would allow states more federal funding for substance use disorder services over the next four years. Though which states may end up participating will depend on several factors, some of the likely contenders would provide either high or modest benefit for Acadia Healthcare Co. Inc. and/or Universal Health Services Inc. , which own behavioral health facilities, with potential areas including Colorado, Connecticut, D.C., Ohio and Missouri, Harris said. The measure, which has bipartisan and bicameral support, additionally aims to increase access to medications for opioid addiction, which could lift drugmakers like Teva Pharmaceutical Industries Ltd. , Mallinckrodt PLC and Alkermes PLC , Harris said; the legislation is also "slightly negative" for Centene , Molina and WellCare , and excludes a provision that might have helped Heron Therapeutics . The S&P 500 has risen 7.3% over the last three months and the Dow Jones Industrial Average has lifted 9.3%.
- Zacks•last month
Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?
Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.
Markit•last monthSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Simply Wall St.•last month
Why Alkermes plc (NASDAQ:ALKS) Is A Financially Healthy Company
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Alkermes plc (NASDAQ:ALKS), with a market cap of US$6.23b, are often out of the spotlight.Read More...
- Zacks•last month
Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo
Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.
- PR Newswire•last month
Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab
DUBLIN, Sept. 10, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the FDA-approved PD-1 inhibitor KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. ALKS 4230 is an engineered fusion protein designed to preferentially bind and signal through the intermediate affinity interleukin-2 (IL-2) receptor complex, thereby selectively activating and increasing the number of immunostimulatory tumor-killing immune cells while avoiding the expansion of immunosuppressive cells that interfere with anti-tumor response.
Markit•2 months agoSee what the IHS Markit Score report has to say about Alkermes PLC.
Alkermes PLC NASDAQ/NGS:ALKS
Market Realist•2 months agoAlkermes: Product Portfolio Performance Update
In the second quarter, Alkermes’ (AKLS) Aristada generated revenues of $33.6 million—compared to $22.7 million in the second quarter of 2017, which reflects~48% growth YoY (year-over-year).
